Related Experiment Videos
[Antinuclear antibodies in multiple sclerosis]
A Antigüedad1, J Ruiz, M M Mendibe
1Servicio y Cátedra de Neurología, Hospital de Cruces, Universidad del País Vasco, Baracaldo, Vizcaya.
Neurologia (Barcelona, Spain)
|June 1, 1997
Summary
Antinuclear antibodies (ANA) were found in 15% of multiple sclerosis (MS) patients, but titers normalized over time. ANA testing has low diagnostic value for MS.
Area of Science:
- Immunology
- Neurology
Context:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- The role of autoantibodies, such as antinuclear antibodies (ANA), in MS pathogenesis is not fully understood.
- Previous research has not extensively studied the prevalence and evolution of ANA in MS patients.
Purpose:
- To investigate the prevalence of circulating antinuclear antibodies (ANA) in patients with multiple sclerosis (MS).
- To analyze the temporal changes in ANA titers among MS patients with initially positive results.
- To assess the diagnostic utility of ANA determination in the context of MS.
Summary:
- A study examined 147 multiple sclerosis (MS) patients and found antinuclear antibodies (ANA) positivity in 15% (22 patients) at initial analysis, compared to 6.1% in a control group with non-autoimmune neurological diseases.
- For MS patients with positive ANA, titers normalized in 94.7% within a mean period of 22.5 months.
- This study is the first to document the evolution of ANA titers in MS patients.
Impact:
- The fluctuating nature of ANA in MS suggests caution when interpreting other autoantibody titers for etiopathogenetic hypotheses or diagnosing co-occurring conditions.
- ANA determination appears to have limited diagnostic value in the management of multiple sclerosis.
- Findings highlight the dynamic immunological landscape in MS and the need for careful interpretation of serological markers.